Hennion & Walsh Asset Management, Inc. Travere Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 40,448 shares of TVTX stock, worth $616,023. This represents 0.02% of its overall portfolio holdings.
Number of Shares
40,448
Previous 40,790
0.84%
Holding current value
$616,023
Previous $314,000
5.73%
% of portfolio
0.02%
Previous 0.02%
Shares
11 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.8MCall Options Held
137KPut Options Held
181K-
Black Rock Inc. New York, NY7.64MShares$116 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$114 Million0.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$112 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$101 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.48MShares$68.3 Million1.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $977M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...